User profiles for John Seibyl

John P. Seibyl

Institute for Neurodegenerative Disorders
Verified email at indd.org
Cited by 40251

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses

JH Krystal, LP Karper, JP Seibyl… - Archives of general …, 1994 - jamanetwork.com
Background: To characterize further behavioral, cognitive, neuroendocrine, and physiological
effects of subanesthetic doses of ketamine hydrochloride in healthy human subjects. …

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

…, SS Zoghbi, RM Baldwin, JP Seibyl… - Proceedings of the …, 1996 - National Acad Sciences
The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic
transmission is associated with this illness, but direct observation of abnormalities of dopamine …

[HTML][HTML] MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder

…, TM Scott, RA Bronen, JP Seibyl… - The American journal …, 1995 - ncbi.nlm.nih.gov
Objective Studies in nonhuman primates suggest that high levels of cortisol associated with
stress have neurotoxic effects on the hippocampus, a brain structure involved in memory. …

The Parkinson progression marker initiative (PPMI)

…, C Meunier, A Rudolph, C Casaceli, J Seibyl… - Progress in …, 2011 - Elsevier
The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to improve …

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort

…, R Gil, J Krystal, RM Baldwin, JP Seibyl… - American journal of …, 1998 - Am Psychiatric Assoc
OBJECTIVE: The authors previously observed an increase in striatal dopamine transmission
following amphetamine challenge in 15 untreated patients with schizophrenia compared to …

[HTML][HTML] CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER …

O Hansson, J Seibyl, E Stomrud, H Zetterberg… - Alzheimer's & …, 2018 - Elsevier
Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF)
immunoassay results were concordant with positron emission tomography (PET) and predicted …

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

…, A Lang, K Marek, M McDermott, J Seibyl… - Archives of …, 2004 - europepmc.org
Objective To compare initial treatment with pramipexole vs levodopa in early Parkinson
disease, followed by levodopa supplementation, with respect to the development of …

Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale

…, L Brenner, J Erdos, DC d'Souza, JP Seibyl… - Schizophrenia …, 2010 - Elsevier
BACKGROUND: Nonlocalizing neurologic deficits detectable by clinical evaluation–“soft
signs”–are a robust finding in patients diagnosed with schizophrenia, but their conceptual and …

[HTML][HTML] Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane and single photon …

…, CB Nemeroff, N Rajeevan, RM Baldwin, JP Seibyl… - Biological …, 1998 - Elsevier
Background: Prior research has suggested reductions in the density of serotonin transporter
(SERT) binding sites in blood platelets and post-mortem brain tissue of depressed patients. …

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

…, F Hiemeyer, SM Wittemer-Rump, J Seibyl… - The Lancet …, 2011 - thelancet.com
Background Imaging with amyloid-β PET can potentially aid the early and accurate
diagnosis of Alzheimer's disease. Florbetaben ( 18 F) is a promising 18 F-labelled amyloid-β-…